RAD52 and ovarian carcinoma: They also prompted development of RAD52 inhibitors, which could lead to novel cancer therapies against hereditary breast cancer and ovarian cancer and other types of cancers in which RAD52 is essential for cell viability due to various deficiencies in HR.